Wells Fargo lifts REGN target to $925 on execution
Alpha Vantage · Investing.com · · AI-summarised by FinFlash
Wells Fargo has increased its price target for Regeneron Pharmaceuticals (NASDAQ: REGN) shares to $925 from $750, maintaining an "Equal Weight" rating, citing strong commercial execution. The stock is currently trading near its 52-week high after a recent surge. The firm projects $83 per share in 2027 earnings, with potential for further multiple expansion as valuation is considered reasonable.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.